Collplant biotechnologies reports 2024 financial results and provides a corporate update

Collplant announces six-month study data from its regenerative breast implant program, which could provide a revolutionary alternative to women for aesthetic or medical purposes and aims to address a $3 billion market opportunity recently received a $2 million development payment from abbvie conference call to be held today at 10:00 a.m. u.s. edt rehovot, israel , march 26, 2025 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), or "collplant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced its 2024 financial results and provided a corporate update.
CLGN Ratings Summary
CLGN Quant Ranking